|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma显示文摘AIM: To conduct a retrospective study in 400 chronic hepatitis B patients in order to identify hepatitis B viral factors associated with complications of liver disease or development of hepatocellular carcinoma.METHODS: The mean follow-up time was 83.6 ± 39.6 mo. Alpha-fetoprotein test and abdominal ultrasound were used for cancer surveillance. Hepatitis B basal core promoter mutants, precore mutants, genotypes, hepatitis B viral DNA (HBV DNA) level and hepatitis B e antigen (HBeAg) were measured. Univariate analysis and logistic regression were used to assess odds ratios for viral factors related to liver deaths and hepatocellular carcinoma development. RESULTS: During follow-up, 38 patients had liver deaths not related to hepatocellular carcinoma. On multivariate analysis, older age [odds ratio: 95.74 (12.13-891.31); P < 0.0001], male sex [odds ratio: 7.61 (2.20-47.95); P = 0.006], and higher log10 HBV DNA [odds ratio: 4.69 (1.16-20.43); P < 0.0001] were independently predictive for these liver related deaths. Also, 31 patients developed hepatocellular carcinoma. Multivariate analysis showed that older age [odds ratio: 26.51 (2.36-381.47); P = 0.007], presence of precore mutants [odds ratio: 4.23 (1.53-19.58); P = 0.02] and presence of basal core promoter mutants [odds ratio: 2.93 (1.24-7.57); P = 0.02] were independent predictors for progression to hepatocellular carcinoma.CONCLUSION: Our results show that high levels of baseline serum HBV DNA are associated with non- hepatocellular carcinoma-related deaths of liver failure, while genetic mutations in the basal core promoter and precore regions are predictive for development of hepatocellular carcinoma. | Myron J Tong Lawrence M Blatt Jia-Horng Kao Jason Tzuying Cheng William G Corey | 2006 | World Journal of Gastroenterology2006，12，41： | 11 |
| 2 | 帕博利珠单抗联合以铂类为基础的化疗治疗非小细胞肺癌合并稳定性脑转移患者的结局:KEYNOTE-021、-189和-407研究的汇总分析显示文摘背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患者和方法对KEYNOTE-021队列G(非鳞癌)、KEYNOTE-189(非鳞癌)和KEYNOTE-407(鳞癌)三项研究晚期NSCLC患者的数据进行汇总分析。患者接受含铂两药化疗和/或35个周期帕博利珠单抗治疗(每3周200 mg)。所有研究均纳入了经治或初治的稳定性脑转移患者(KEYNOTE-189与KEYNOTE-407研究纳入初治脑转移患者)。经治的脑转移患者已处于病情稳定的状态≥2周(KEYNOTE-021队列G患者≥4周),无新发或脑转移病灶扩大的证据且入组前至少3天以上未使用激素。初治的无症状脑转移患者需定期接受脑部影像学检查。结果共纳入1298例患者,其中171例有基线脑转移,1127例无脑转移。两组的中位随访时间(范围)在数据截止时分别为10.9(0.1-35.1)个月和11.0(0.1-34.9)个月。合并脑转移和无脑转移患者的总生存期[0.48(95%CI:0.32-0.70)和0.63(95%CI:0.53-0.75)]和无进展生存期[0.44(95%CI:0.31-0.62)和0.55(95%CI:0.48-0.63)]的风险比(PC/化疗)相似。合并脑转移的患者中,PC组和单用化疗组患者的中位总生存期分别为18.8个月和7.6个月,中位无进展生存期分别为6.9个月和4.1个月。无论是否合并脑转移,PC组患者的客观缓解率都高于单用化疗组,且缓解持续时间有显著延长。合并脑转移的患者中,PC组与单用化疗组的治疗相关不良事件发生率分别为88.2%和82.8%;而无脑转移的患者中,两组治疗相关不良事件的发生率分别为94.5%和90.6%。结论无论是否合并脑转移,与单用化疗相比,帕博利珠单抗联合以铂类为基础的组织学特异性化疗可改善所有PD-L1亚组的临床结局,其中包括PD-L1肿瘤比例评分<1%的患者,并且在晚期NSCLC患者中安全性良好。该方案是晚期NSCLC初治患者的标准方案,并可用于合并稳定性脑转移的患者。 | 周清(翻译校对) Steven F Powell Delvys Rodríguez-Abreu Corey J Langer Ali Tafreshi Luis Paz-Ares Hans-Georg Kopp Jeronimo Rodríguez-Cid Dariusz M Kowalski Ying Cheng Takayasu Kurata Mark M Awad Jinaxin Lin Bin Zhao M Catherine Pietanza Bilal Piperdi Marina C Garassino | 2022 | 中国肺癌杂志2022，25，1： | 6 |
| 3 | A rational approach to catalytic enantionoseletive enolate alkylation using a structurally rigidified and defined chiral quaternary ammonium salt under phase transfer conditions 显示文摘 | COREY E J XU F NOE M C | 1997 | J Am Chem Soc1997，119，12： | 2 |
| 4 | Understanding and Managing the Service Supply Chain 显示文摘 | LISA M ELLRAM WENDY L T COREY B | 2004 | Journal of Supply Chain Management2004，40，4： | 1 |
| 5 | The micromachinery of mechanotransduction in hair cells 显示文摘 | VOLLRATH M A KWAN K Y COREY D P | 2007 | Annu Rev Neurosci2007，30，： | 1 |
| 6 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants显示文摘 | LIMAYE A P COREY L KOELLE D M | 2000 | Lancet2000，356，： | 1 |
| 7 | Relevance of Subcor- tical Stroke in Dysphagia显示文摘 | Cola Monique G Daniels Stephanie K Corey David M | 2010 | Stroke2010，41，3： | 1 |
| 8 | Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding显示文摘 | Corey E A Mirza A M Levandowsky E | 2003 | J Virol2003，77，77： | 1 |
| 9 | Increasing rates of cardiac device infections among medicare beneficiaries: 1990–1999显示文摘 | Christopher H Cabell Paul A Heidenreich Vivian H Chu Christopher M Moore Martin E Stryjewski G.Ralph Corey Vance G Fowler | 2004 | American Heart Journal2004，，4： | 1 |
| 10 | Eruption of bullae within psoriatic plaques: a rare adverse effect of narrowband uhraviolet B (NBUVB) phototherapy 显示文摘 | Corey K Levin NA Hure M | 2012 | Dermatol Online J2012，18，6： | 1 |
| 11 | Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients显示文摘 | Zinman R Corey M Coates AL | 1989 | J Pediatr1989，114，： | 1 |
| 12 | CFTR gene variant for patients with congenital absence of vas deferens显示文摘 | Zielenski J Patrizio P Corey M | 1995 | Am J Hum Genet1995，57，： | 1 |
| 13 | Detection of disseminated prostate cells by reverse transcription-polymerise chain reaction (RT-PCR):Technical and clinical aspects显示文摘 | Corey E Corey M J | 1998 | Int J Cancer1998，77，： | 1 |
| 14 | Targeted therapy for ad- vanced prostate cancer: inhibition of the PI3K/AKT/mTOR path- way 显示文摘 | Morgan T M Koreckij T D Corey E | 2009 | Curr Cancer Drug Targets2009，9，2： | 1 |
| 15 | Myelody splastic syndromes:the complexity of stem-cell diseases显示文摘 | COREY S J MINDEN M D BARBER D L | 2007 | Nat Rev Cancer2007，7，2： | 1 |
| 16 | In search of the haircell gating spring elastic properties of ankyrin and cadherin repeats显示文摘 | Sotomayor M Corey D P Schulten K | | 0，，04： | 1 |
| 17 | Convenient synthesis of 4-amino-3,5-disubstituted pyrazoles in one-step from the corresponding diketo oximes显示文摘 | Tahir M Corey R H Brian P | 2004 | Tetrahedron Lett2004，45，： | 1 |
| 18 | Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits : serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial显示文摘 | Jenkins D J A Kendall C W C Vuksan V Vidgen E Parker T Faulkner D Mehling C C Garsetti M Testolin G Cunnane S C Ryan bl A Corey P N | 2002 | The American Journal of Clinical Nutrition2002，75，5： | 1 |
| 19 | Relevance of subcortical stroke in dysphagia显示文摘 | ColaMonique G Daniels Stephanic K Corey Dvid M | 2010 | Stroke2010，41，3： | 1 |
| 20 | Understanding and managing the services supply chain显示文摘 | LISA M E WENDY L T COREY B | 2004 | Journal of Supply Chain Management2004，40，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员